Impact of Insurance Provider on Overall Costs in Failed Back Surgery Syndrome: A Cost Study of 122, 827 Patients. Issue 4 (21st March 2017)

• Record Type: Journal Article
• Authors: Elsamadicy, Aladine A.; Farber, Samuel Harrison; Yang, Siyun; Hussaini, Syed Mohammed Qasim; Murphy, Kelly R.; Sergesketter, Amanda; Suryadevara, Carter M.; Pagadala, Promila; Parente, Beth; Xie, Jichun; Lad, Shivanand P.
• Is Part Of: Neuromodulaton. Volume 20:Issue 4(2017)
• Page Start: 354
• Page End: 360
• Publication Date: 2017-03-21
• Subjects: Cost -- FBSS -- insurance disparities -- Medicaid -- Medicare -- SCS; Central nervous system -- Physiology -- Periodicals; Central nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ner.12584
• Languages: English
• ISSNs: 1094-7159

Abstract

Abstract : Objectives: Failed back surgery syndrome (FBSS) affects 40% of patients following spine surgery with estimated costs of $20 billion to the US health care system. The aim of this study was to assess the cost differences across the different insurance providers for FBSS patients. Methods: A retrospective longitudinal study was performed using the Truven MarketScan ® database to identify FBSS patients from 2001 to 2012. Patients were grouped into Commercial, Medicaid, or Medicare cohorts. We collected one‐year prior to FBSS diagnosis (baseline), then at year of spinal cord stimulation (SCS)‐implantation and nine‐year post‐SCS implantation cost outcomes. Results: We identified 122, 827 FBSS patients, with 117, 499 patients who did not undergo an SCS‐implantation (Commercial: n = 49, 075, Medicaid: n = 23, 180, Medicare: n = 45, 244) and 5328 who did undergo an SCS implantation (Commercial: n = 2279, Medicaid: n = 1003, Medicare: n = 2046). Baseline characteristics were similar between the cohorts, with the Medicare‐cohort being significantly older. Over the study period, there were significant differences in overall cost metrics between the cohorts who did not undergo SCS implantation with the Medicaid‐cohort had the lowest annual median (interquartile range) total cost ( Medicaid: $4530.4 [$1440.6, $11, 973.5], Medicare: $7292.0 [$3371.4, $13, 989.4], Commercial: $4944.3 [$363.8, $13, 294.0], p < 0.0001 ). However, when comparing the patients who underwent SCS implantation, the commercial‐cohort had the lowest annual median (interquartile range) total costs ( Medicaid: $4045.6 [$1146.9, $11, 533.9], Medicare: $7158.1 [$3160.4, $13, 916.6], Commercial: $2098.1 [$0.0, $8919.6], p < 0.0001 ). Conclusions: Our study demonstrates a significant difference in overall costs between various insurance providers in the management of FBSS, with Medicaid‐insured patients having lower overall costs compared to Commercial‐ and Medicare‐patients. SCS is cost‐effective across all insurance groups (Commercial > Medicaid > Medicare) beginning at two years and continuing through nine‐year follow‐up. Further studies are necessary to understand the cost differences between these insurance providers, in hopes of reducing unnecessary health care expenditures for patients with FBSS.